Showing 3591-3600 of 7372 results for "".
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- Sinclair Will Market and Distribute Silhouette InstaLift in UShttps://practicaldermatology.com/news/sinclair-to-market-and-distribute-silhouette-instalift-in-the-us/2457773/Silhouette Lift, Inc.. a Sinclair Pharma Company, is now handling all of the commercial aspects of the Silhouette InstaLift portfolio of resorbable skin lifting sutures including sales and marketing, and order fulfillment. They are also relaunching
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs
- Allergan Appoints Carrie Strom as Senior Vice President, U.S. Medical Aestheticshttps://practicaldermatology.com/news/allergan-appoints-carrie-strom-as-senior-vice-president-us-medical-aesthetics/2457776/Carrie Strom is Allergan’s new Senior Vice President, U.S. Medical Aesthetics, a portfolio of brands including BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® Collection of Fillers, Natrelle® col
- Daily Aspirin Linked to Higher Melanoma Risk in Menhttps://practicaldermatology.com/news/daily-aspirin-linked-to-higher-melanoma-risk-in-men/2457779/Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who don’t, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population, the study showed. The study collected medical record
- Tutublue Launches Men's Line of Sunsafe Activewearhttps://practicaldermatology.com/news/tutu-blue-launches-mens-line-of-sunsafe-activewear/2457780/Tutublue, the sun-protective activewear brand, is unveiling a line of men's rash guards and full suits for Summer 2018. Tutublue, designed by California actress and entrepreneur
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Bath Emollients Don't Add Much to Standard Eczema Carehttps://practicaldermatology.com/news/bath-emollients-dont-add-much-to-standard-eczema-care/2457784/Emollient bath additives provide no meaningful benefit when used in addition to standard eczema care in children, according to research in the BMJ. UK researchers, led by Miriam Santer, MBBChir
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA
- Cellulite Market Expected to Growhttps://practicaldermatology.com/news/cellulite-market-expected-to-grow/2457792/The cellulite treatment market is expected to grow worldwide, as the obesity epidemic grows. Findings are in the comprehensive research report by Future Market Insights entitled “Cellulite Treatment Market